Leading UK Pharmacies trust Deltera
Deliver the latest in GLP-1/GIP receptor agonist therapy. The Mounjaro PGD enables pharmacists to provide Tirzepatide for weight management, supported by Deltera’s robust digital pre-screening to verify BMI and eligibility.
A Fully Digital Clinical Platform
Integrated Bookings and Payments
Secure & Connected Patient Records
Ditch the paperwork with secure digital records. Deltera automatically shares treatment summaries with the patient’s and sends the required notification to their GP instantly.
Training and Eligibility Requirements
To ensure clinical safety and regulatory compliance, all practitioners using this PGD must meet the following professional standards:
- Professional Registration: Must be a registered healthcare professional (e.g., Pharmacist) with a valid GPhC or PSNI registration and personal professional indemnity insurance.
- Clinical Competency: Practitioners must be self-certified as competent in the specific clinical area covered by this PGD and stay up to date with relevant national guidelines (e.g., The Green Book or NICE clinical summaries).
- Mandatory Training: Current certification in Basic Life Support (BLS) and the management of anaphylaxis is required for all injectable services.
- PGD Authorisation: The practitioner must have read and signed the PGD document within the Deltera Clinical Dashboard, with the authorisation counter-signed by the designated organisational lead or Superintendent.
- Premises Standards: Services must be conducted in a private consultation room that meets national standards for patient confidentiality and clinical safety.
Speak to the clinicians behind the platform
We understand the complexities of PGDs and clinical governance in the UK. Schedule a meeting with our team to see how we can help you navigate the changing landscape of community pharmacy.
Access related PGDs
FAQs
Eligibility is based on BMI thresholds (typically BMI ≥30, or ≥27 with weight-related comorbidities). Deltera’s portal allows patients to enter their details privately for pharmacist review.
Yes. The PGD manages the step-up dosing from 2.5mg up to 15mg. Deltera’s records ensure the patient is safely titrated based on their tolerance and weight loss progress.
Patients can report feedback through their portal. The pharmacist uses the Deltera consultation notes to track any GI side effects, ensuring the patient is on the most appropriate dose.
Switching protocols are built into our clinical logic. Deltera helps pharmacists manage the washout period or transition steps safely according to the latest clinical guidance.
Still have questions?
Our team are here to support you.
Discover Deltera Practice Management
Deltera Practice Management digitalises your private pharmacy services, providing the complete pharmacy software package to offer a full range of Patient Group Directions (PGDs). Gain the oversight and efficiency you need to thrive.
